New hope for hard-to-treat colorectal cancer: targeted drug aims to extend life
NCT ID NCT07213570
First seen Nov 01, 2025 · Last updated May 25, 2026 · Updated 28 times
Summary
This study tests whether the drug regorafenib can help people with a specific type of advanced colorectal cancer (RAS-mutant) live longer without their cancer growing. About 60 adults whose cancer has spread and who have already received one prior treatment will take regorafenib. The goal is to see if this approach can control the disease while maintaining quality of life.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL CANCER METASTATIC are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Istituto Nazionale Tumori | "Fondazione Pascale"
RECRUITINGNaples, Italy, Italy
Conditions
Explore the condition pages connected to this study.